Your browser doesn't support javascript.
loading
Nivolumab-induced immune-mediated neurotoxicity in Hodgkin lymphoma.
Lopez, James; Yarlagadda, Naveen; Gheith, Zaid; Mohan, Meera; Sasapu, Appalanaidu.
Afiliación
  • Lopez J; Department of Hematology/Oncology, University of Arkansas for Medical SciencesLittle RockArkansas.
  • Yarlagadda N; Department of Hematology/Oncology, University of Arkansas for Medical SciencesLittle RockArkansas.
  • Gheith Z; Department of Hematology/Oncology, University of Arkansas for Medical SciencesLittle RockArkansas.
  • Mohan M; Department of Hematology/Oncology, University of Arkansas for Medical SciencesLittle RockArkansas.
  • Sasapu A; Department of Hematology/Oncology, University of Arkansas for Medical SciencesLittle RockArkansas.
Proc (Bayl Univ Med Cent) ; 33(1): 59-61, 2020 Jan.
Article en En | MEDLINE | ID: mdl-32063772
Nivolumab, a monoclonal antibody against programmed cell death-1 used to treat multiple cancers, has fewer side effects than traditional chemotherapy but has displayed a propensity to cause a host of immune-related adverse events. We describe a case of nivolumab immune-mediated neurotoxicity in a 42-year-old Hispanic man with relapsed Hodgkin lymphoma who presented with unilateral facial droop, dysarthria, and dysphagia 1 week after receiving nivolumab. His symptoms rapidly improved with steroids, intravenous immunoglobulin, and infliximab.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Proc (Bayl Univ Med Cent) Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Proc (Bayl Univ Med Cent) Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos